1 change Guidance, last 7 days

PRAC Recommends EU Market Withdrawal of Levamisole Medicines

The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the withdrawal of marketing authorizations for medicines containing levamisole from the EU market. This decision is based on a re-evaluation of safety data, concluding that the risks associated with these drugs outweigh their benefits for treating parasitic worm infections.

Priority review Guidance Pharmaceuticals

Get alerts for ""

We'll email you when new changes match this search.

Free. Unsubscribe anytime.